The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Recombinant Non-Glycosylated Proteins Biosimilars-Global Market Insights and Sales Trends 2025
Synopsis
Recombinant non-glycosylated proteins include human growth hormone, granulocyte colony-stimulating factor, interferons, and insulin. The statistic scope in this report is Recombinant non-glycosylated proteins biosimilars.
The global Recombinant Non-Glycosylated Proteins Biosimilars market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Recombinant Non-Glycosylated Proteins Biosimilars in various end use industries. The expanding demands from the Oncology, Chronic Diseases, Autoimmune Diseases and Blood Disorders, are propelling Recombinant Non-Glycosylated Proteins Biosimilars market. Insulin, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the rHGH segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Recombinant Non-Glycosylated Proteins Biosimilars, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Recombinant Non-Glycosylated Proteins Biosimilars market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Recombinant Non-Glycosylated Proteins Biosimilars market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Recombinant Non-Glycosylated Proteins Biosimilars sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Recombinant Non-Glycosylated Proteins Biosimilars covered in this report include Sandoz, Pfizer, Teva Pahrmaceutical, Celltrion, Biocon, Amgen, Samsung Biologics, Mylan and Dr. Reddy's Laboratories, etc.
The global Recombinant Non-Glycosylated Proteins Biosimilars market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Sandoz
Pfizer
Teva Pahrmaceutical
Celltrion
Biocon
Amgen
Samsung Biologics
Mylan
Dr. Reddy's Laboratories
Stada Arzneimittel AG
Global Recombinant Non-Glycosylated Proteins Biosimilars market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Recombinant Non-Glycosylated Proteins Biosimilars market, Segment by Type:
Insulin
rHGH
Interferon
Global Recombinant Non-Glycosylated Proteins Biosimilars market, by Application
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Other Diseases
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Recombinant Non-Glycosylated Proteins Biosimilars companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Recombinant non-glycosylated proteins include human growth hormone, granulocyte colony-stimulating factor, interferons, and insulin. The statistic scope in this report is Recombinant non-glycosylated proteins biosimilars.
The global Recombinant Non-Glycosylated Proteins Biosimilars market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Recombinant Non-Glycosylated Proteins Biosimilars in various end use industries. The expanding demands from the Oncology, Chronic Diseases, Autoimmune Diseases and Blood Disorders, are propelling Recombinant Non-Glycosylated Proteins Biosimilars market. Insulin, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the rHGH segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Recombinant Non-Glycosylated Proteins Biosimilars, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Recombinant Non-Glycosylated Proteins Biosimilars market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Recombinant Non-Glycosylated Proteins Biosimilars market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Recombinant Non-Glycosylated Proteins Biosimilars sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Recombinant Non-Glycosylated Proteins Biosimilars covered in this report include Sandoz, Pfizer, Teva Pahrmaceutical, Celltrion, Biocon, Amgen, Samsung Biologics, Mylan and Dr. Reddy's Laboratories, etc.
The global Recombinant Non-Glycosylated Proteins Biosimilars market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Sandoz
Pfizer
Teva Pahrmaceutical
Celltrion
Biocon
Amgen
Samsung Biologics
Mylan
Dr. Reddy's Laboratories
Stada Arzneimittel AG
Global Recombinant Non-Glycosylated Proteins Biosimilars market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Recombinant Non-Glycosylated Proteins Biosimilars market, Segment by Type:
Insulin
rHGH
Interferon
Global Recombinant Non-Glycosylated Proteins Biosimilars market, by Application
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Other Diseases
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Recombinant Non-Glycosylated Proteins Biosimilars companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Recombinant Non-Glycosylated Proteins Biosimilars
1.1 Recombinant Non-Glycosylated Proteins Biosimilars Market Overview
1.1.1 Recombinant Non-Glycosylated Proteins Biosimilars Product Scope
1.1.2 Recombinant Non-Glycosylated Proteins Biosimilars Market Status and Outlook
1.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Region (2018-2029)
1.4 Global Recombinant Non-Glycosylated Proteins Biosimilars Historic Market Size by Region (2018-2023)
1.5 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Recombinant Non-Glycosylated Proteins Biosimilars Market Size (2018-2029)
1.6.1 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size (2018-2029)
1.6.2 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size (2018-2029)
1.6.3 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size (2018-2029)
1.6.4 Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size (2018-2029)
1.6.5 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size (2018-2029)
2 Recombinant Non-Glycosylated Proteins Biosimilars Market by Type
2.1 Introduction
2.1.1 Insulin
2.1.2 rHGH
2.1.3 Interferon
2.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Historic Market Size by Type (2018-2023)
2.2.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Recombinant Non-Glycosylated Proteins Biosimilars Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Recombinant Non-Glycosylated Proteins Biosimilars Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Recombinant Non-Glycosylated Proteins Biosimilars Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Recombinant Non-Glycosylated Proteins Biosimilars Revenue Breakdown by Type (2018-2029)
3 Recombinant Non-Glycosylated Proteins Biosimilars Market Overview by Application
3.1 Introduction
3.1.1 Oncology
3.1.2 Chronic Diseases
3.1.3 Autoimmune Diseases
3.1.4 Blood Disorders
3.1.5 Growth Hormone Deficiency
3.1.6 Infectious Diseases
3.1.7 Other Diseases
3.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Historic Market Size by Application (2018-2023)
3.2.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Recombinant Non-Glycosylated Proteins Biosimilars Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Recombinant Non-Glycosylated Proteins Biosimilars Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Recombinant Non-Glycosylated Proteins Biosimilars Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Recombinant Non-Glycosylated Proteins Biosimilars Revenue Breakdown by Application (2018-2029)
4 Recombinant Non-Glycosylated Proteins Biosimilars Competition Analysis by Players
4.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Recombinant Non-Glycosylated Proteins Biosimilars as of 2022)
4.3 Date of Key Players Enter into Recombinant Non-Glycosylated Proteins Biosimilars Market
4.4 Global Top Players Recombinant Non-Glycosylated Proteins Biosimilars Headquarters and Area Served
4.5 Key Players Recombinant Non-Glycosylated Proteins Biosimilars Product Solution and Service
4.6 Competitive Status
4.6.1 Recombinant Non-Glycosylated Proteins Biosimilars Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Sandoz
5.1.1 Sandoz Profile
5.1.2 Sandoz Main Business
5.1.3 Sandoz Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions
5.1.4 Sandoz Recombinant Non-Glycosylated Proteins Biosimilars Revenue (US$ Million) & (2018-2023)
5.1.5 Sandoz Recent Developments
5.2 Pfizer
5.2.1 Pfizer Profile
5.2.2 Pfizer Main Business
5.2.3 Pfizer Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions
5.2.4 Pfizer Recombinant Non-Glycosylated Proteins Biosimilars Revenue (US$ Million) & (2018-2023)
5.2.5 Pfizer Recent Developments
5.3 Teva Pahrmaceutical
5.3.1 Teva Pahrmaceutical Profile
5.3.2 Teva Pahrmaceutical Main Business
5.3.3 Teva Pahrmaceutical Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions
5.3.4 Teva Pahrmaceutical Recombinant Non-Glycosylated Proteins Biosimilars Revenue (US$ Million) & (2018-2023)
5.3.5 Celltrion Recent Developments
5.4 Celltrion
5.4.1 Celltrion Profile
5.4.2 Celltrion Main Business
5.4.3 Celltrion Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions
5.4.4 Celltrion Recombinant Non-Glycosylated Proteins Biosimilars Revenue (US$ Million) & (2018-2023)
5.4.5 Celltrion Recent Developments
5.5 Biocon
5.5.1 Biocon Profile
5.5.2 Biocon Main Business
5.5.3 Biocon Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions
5.5.4 Biocon Recombinant Non-Glycosylated Proteins Biosimilars Revenue (US$ Million) & (2018-2023)
5.5.5 Biocon Recent Developments
5.6 Amgen
5.6.1 Amgen Profile
5.6.2 Amgen Main Business
5.6.3 Amgen Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions
5.6.4 Amgen Recombinant Non-Glycosylated Proteins Biosimilars Revenue (US$ Million) & (2018-2023)
5.6.5 Amgen Recent Developments
5.7 Samsung Biologics
5.7.1 Samsung Biologics Profile
5.7.2 Samsung Biologics Main Business
5.7.3 Samsung Biologics Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions
5.7.4 Samsung Biologics Recombinant Non-Glycosylated Proteins Biosimilars Revenue (US$ Million) & (2018-2023)
5.7.5 Samsung Biologics Recent Developments
5.8 Mylan
5.8.1 Mylan Profile
5.8.2 Mylan Main Business
5.8.3 Mylan Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions
5.8.4 Mylan Recombinant Non-Glycosylated Proteins Biosimilars Revenue (US$ Million) & (2018-2023)
5.8.5 Mylan Recent Developments
5.9 Dr. Reddy's Laboratories
5.9.1 Dr. Reddy's Laboratories Profile
5.9.2 Dr. Reddy's Laboratories Main Business
5.9.3 Dr. Reddy's Laboratories Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions
5.9.4 Dr. Reddy's Laboratories Recombinant Non-Glycosylated Proteins Biosimilars Revenue (US$ Million) & (2018-2023)
5.9.5 Dr. Reddy's Laboratories Recent Developments
5.10 Stada Arzneimittel AG
5.10.1 Stada Arzneimittel AG Profile
5.10.2 Stada Arzneimittel AG Main Business
5.10.3 Stada Arzneimittel AG Recombinant Non-Glycosylated Proteins Biosimilars Products, Services and Solutions
5.10.4 Stada Arzneimittel AG Recombinant Non-Glycosylated Proteins Biosimilars Revenue (US$ Million) & (2018-2023)
5.10.5 Stada Arzneimittel AG Recent Developments
6 North America
6.1 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Recombinant Non-Glycosylated Proteins Biosimilars Market Dynamics
11.1 Recombinant Non-Glycosylated Proteins Biosimilars Industry Trends
11.2 Recombinant Non-Glycosylated Proteins Biosimilars Market Drivers
11.3 Recombinant Non-Glycosylated Proteins Biosimilars Market Challenges
11.4 Recombinant Non-Glycosylated Proteins Biosimilars Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
